Abstract | PURPOSE OF REVIEW: Hormonal treatment is one of the cornerstones of management for breast cancer. For many years, tamoxifen represented the gold standard. The development of aromatase inhibitors has, however, challenged the primary role of tamoxifen. Randomized studies evaluating the role of aromatase inhibitors in both the metastatic and adjuvant settings, in postmenopausal women, have been conducted. This article describes the most recent available data for these trials. RECENT FINDINGS: SUMMARY:
|
Authors | Richard E Gould, Agustin A Garcia |
Journal | Current opinion in obstetrics & gynecology
(Curr Opin Obstet Gynecol)
Vol. 18
Issue 1
Pg. 41-6
(Feb 2006)
ISSN: 1473-656X [Electronic] England |
PMID | 16493259
(Publication Type: Journal Article, Review)
|
Chemical References |
- Aromatase Inhibitors
- Tamoxifen
|
Topics |
- Aromatase Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Breast Neoplasms
(drug therapy)
- Clinical Trials as Topic
- Female
- Humans
- Postmenopause
- Tamoxifen
(therapeutic use)
|